KalVista Pharmaceuticals (KALV) Short Interest Ratio & Short Volume $11.85 +0.10 (+0.85%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$12.04 +0.19 (+1.60%) As of 10/3/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KalVista Pharmaceuticals Short Interest DataKalVista Pharmaceuticals (KALV) has a short interest of 11.16 million shares. This marks a 5.68% increase in short interest from the previous month. The short interest ratio (days to cover) is 8.8, indicating that it would take 8.8 days of the average trading volume of 1.45 million shares to cover all short positions.Current Short Interest11,160,000 sharesPrevious Short Interest10,560,000 sharesChange Vs. Previous Month+5.68%Dollar Volume Sold Short$152.00 millionShort Interest Ratio8.8 Days to CoverLast Record DateSeptember 15, 2025Outstanding Shares50,520,000 sharesPercentage of Shares Shorted22.09%Today's Trading Volume1,736,471 sharesAverage Trading Volume1,445,013 sharesToday's Volume Vs. Average120% Short Selling KalVista Pharmaceuticals? Sign up to receive the latest short interest report for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartKALV Short Interest Over TimeKALV Days to Cover Over TimeKALV Percentage of Float Shorted Over Time KalVista Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 9/15/202511,160,000 shares $152.00 million +5.7%N/A8.8 $13.62 8/31/202510,560,000 shares $142.14 million +5.2%21.9%8.4 $13.46 8/15/202510,040,000 shares $129.32 million -0.2%N/A8.4 $12.88 7/31/202510,060,000 shares $137.12 million +8.8%22.5%8.7 $13.63 7/15/20259,250,000 shares $140.32 million +8.8%N/A8.5 $15.17 6/30/20258,500,000 shares $96.14 million +36.0%19.1%8.5 $11.31 6/15/20256,250,000 shares $81 million +0.5%14.0%8.5 $12.96 5/31/20256,220,000 shares $73.15 million +1.8%14.1%10.5 $11.76 5/15/20256,110,000 shares $71.24 million +4.3%13.8%10 $11.66 4/30/20255,860,000 shares $80.69 million -5.6%N/A9.9 $13.77 Get the Latest News and Ratings for KALV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 4/15/20256,210,000 shares $74.64 million +6.0%14.0%11.2 $12.02 3/31/20255,860,000 shares $67.62 million +0.3%13.2%11.2 $11.54 3/15/20255,840,000 shares $73.58 million +5.4%13.2%12.9 $12.60 2/28/20255,540,000 shares $63.16 million -5.0%12.5%13.3 $11.40 2/15/20255,830,000 shares $56.90 million -18.2%13.2%15.7 $9.76 1/31/20257,130,000 shares $63.53 million -6.1%N/A19.3 $8.91 1/15/20257,590,000 shares $59.66 million +1.9%N/A21 $7.86 12/31/20247,450,000 shares $63.10 million +3.8%N/A21.5 $8.47 12/15/20247,180,000 shares $62.39 million -1.1%N/A17.8 $8.69 11/30/20247,260,000 shares $73.04 million -1.5%N/A17.6 $10.06 11/15/20247,370,000 shares $69.94 million +7.3%N/A17.7 $9.49 10/31/20246,870,000 shares $70.55 million +0.9%N/A19 $10.27 10/15/20246,810,000 shares $81.58 million +4.6%N/A20.1 $11.98 9/30/20246,510,000 shares $75.39 million +13.8%N/A17 $11.58 9/15/20245,720,000 shares $63.72 million +1.2%N/A15.6 $11.14 8/31/20245,650,000 shares $75.65 million -0.5%N/A17.4 $13.39 8/15/20245,680,000 shares $72.65 million -5.0%N/A17.9 $12.79 7/31/20245,980,000 shares $86.95 million -5.5%N/A18.3 $14.54 7/15/20246,330,000 shares $94.70 million +7.7%N/A18.4 $14.96 6/30/20245,880,000 shares $69.27 million +4.3%N/A17.7 $11.78 6/15/20245,640,000 shares $68.07 million +2.2%N/A15.4 $12.07 5/31/20245,520,000 shares $64.42 million -4.2%N/A14.1 $11.67 5/15/20245,760,000 shares $69.18 million +4.0%N/A11.7 $12.01 4/30/20245,540,000 shares $62.88 million -4.8%N/A7.4 $11.35 4/15/20245,820,000 shares $68.33 million +5.4%N/A7.3 $11.74 3/31/20245,520,000 shares $65.47 million +12.2%N/A6.8 $11.86 3/15/20244,920,000 shares $58.70 million +9.1%N/A6.4 $11.93 2/29/20244,510,000 shares $61.56 million +50.8%18.6%5.9 $13.65 2/15/20242,990,000 shares $44.13 million +21.1%12.4%4.4 $14.76 1/31/20242,470,000 shares $38.95 million -10.5%12.9%6.1 $15.77 1/15/20242,760,000 shares $35.77 million -25.2%14.2%8.3 $12.96 12/31/20233,690,000 shares $45.20 million +5.7%18.7%11.8 $12.25 12/15/20233,490,000 shares $37.27 million -9.6%16.7%10.8 $10.68 11/30/20233,860,000 shares $32.58 million -3.5%18.2%13.4 $8.44 11/15/20234,000,000 shares $30.76 million -3.4%19.0%13.9 $7.69 10/31/20234,140,000 shares $35.15 million -10.8%17.3%14.8 $8.49 10/15/20234,640,000 shares $42.13 million +4.7%N/A16.9 $9.08 9/30/20234,430,000 shares $42.66 million +9.1%N/A16.9 $9.63 9/15/20234,060,000 shares $39.87 million +4.6%N/A19.4 $9.82 8/31/20233,880,000 shares $42.10 million -5.4%N/A19.1 $10.85 8/15/20234,100,000 shares $44.32 million +2.8%19.7%21.4 $10.81 7/31/20233,990,000 shares $40.30 million +2.3%18.3%21 $10.10 7/15/20233,900,000 shares $37.60 million +3.7%17.9%21 $9.64 6/30/20233,760,000 shares $33.84 million +0.8%17.3%18.5 $9.00 6/15/20233,730,000 shares $35.92 million +3.9%17.2%17.2 $9.63 5/31/20233,590,000 shares $35.00 million +5.0%16.5%14.6 $9.75 5/15/20233,420,000 shares $34.58 million +4.3%15.8%12.6 $10.11 4/30/20233,280,000 shares $27.98 million +17.1%14.0%11.5 $8.53 4/15/20232,800,000 shares $22.15 million +3.3%12.0%8.7 $7.91 3/31/20232,710,000 shares $21.30 million +10.2%11.6%8 $7.86 3/15/20232,460,000 shares $18.33 million +13.4%N/A7 $7.45 2/28/20232,170,000 shares $15.91 million -19.6%N/A6.3 $7.33 2/15/20232,700,000 shares $20.87 million -0.4%N/A8.6 $7.73 1/31/20232,710,000 shares $21.57 million +26.6%N/A8.9 $7.96 1/15/20232,140,000 shares $15.19 million -10.5%N/A6.7 $7.10 12/30/20222,390,000 shares $16.16 million +14.9%10.2%7.4 $6.76 12/15/20222,080,000 shares $11.90 million No Change10.4%4.7 $5.72 11/30/20222,080,000 shares $11.21 million No Change10.4%5.1 $5.39 11/15/20222,080,000 shares $10.86 million -8.8%10.4%5.1 $5.22 10/31/20222,280,000 shares $11.56 million -0.4%10.9%5.5 $5.07 10/15/20222,290,000 shares $10.44 million -10.2%10.9%6.2 $4.56 9/30/20222,550,000 shares $37.00 million +3.7%12.2%7.7 $14.51 9/15/20222,460,000 shares $36.43 million +4.7%11.8%13.2 $14.81 8/31/20222,350,000 shares $38.70 million +14.6%11.2%10.7 $16.47 8/15/20222,050,000 shares $32.41 million +8.5%9.8%7.3 $15.81 7/31/20221,890,000 shares $23.34 million +2.7%9.0%6.1 $12.35 7/15/20221,840,000 shares $22.69 million +3.4%8.7%5.7 $12.33 6/30/20221,780,000 shares $17.52 million -16.8%8.5%5.3 $9.84 6/15/20222,140,000 shares $19.07 million +58.5%10.2%6.4 $8.91 5/31/20221,350,000 shares $12.00 million +7.1%6.4%4.6 $8.89 5/15/20221,260,000 shares $12.23 million +37.7%6.0%5.4 $9.71 4/30/2022914,800 shares $11.65 million +4.6%4.3%4.4 $12.73 4/15/2022874,800 shares $12.56 million -19.7%4.2%4.2 $14.36 3/31/20221,090,000 shares $16.07 million -17.4%5.2%5.2 $14.74 3/15/20221,320,000 shares $19.14 million +1.5%6.3%6.6 $14.50 2/28/20221,300,000 shares $20.87 million +13.0%6.2%6.3 $16.05 2/15/20221,150,000 shares $18.95 million -5.7%5.5%5 $16.48 1/31/20221,220,000 shares $15.40 million +15.1%5.8%5.7 $12.62 1/15/20221,060,000 shares $13.29 million +11.9%5.0%5 $12.54 12/31/2021947,400 shares $12.53 million +0.4%4.5%4.7 $13.23 12/15/2021943,800 shares $12.81 million -2.2%4.2%4.4 $13.57 11/30/2021964,800 shares $13.99 million -6.3%4.3%4.4 $14.50 11/15/20211,030,000 shares $17.94 million -5.5%4.6%5.4 $17.42 10/29/20211,090,000 shares $19.60 million -11.4%4.9%5.8 $17.98 10/15/20211,230,000 shares $21.17 million +3.4%5.5%6.9 $17.21 9/30/20211,190,000 shares $20.77 million -14.4%5.4%6.5 $17.45 9/15/20211,390,000 shares $26.76 million -21.0%6.2%7 $19.25 8/31/20211,760,000 shares $35.97 million -4.9%7.9%8.7 $20.44 8/13/20211,850,000 shares $35.72 million -4.2%8.3%8.6 $19.31 7/30/20211,930,000 shares $38.87 million -1.5%9.5%8.5 $20.14 7/15/20211,960,000 shares $43.04 million -2.0%9.9%7.7 $21.96 6/30/20212,000,000 shares $47.92 million +39.9%10.1%6.7 $23.96 6/15/20211,430,000 shares $40.78 million +3.6%7.2%4.6 $28.52 5/28/20211,380,000 shares $37.26 million -3.5%7.0%4.2 $27.00 5/14/20211,430,000 shares $35.91 million +6.7%N/A3.9 $25.11 4/30/20211,340,000 shares $33.81 million +3.1%N/A1.2 $25.23 4/15/20211,300,000 shares $32.40 million +10.2%N/A1.2 $24.92 3/31/20211,180,000 shares $30.33 million +51.8%N/A1.2 $25.70 3/15/2021777,400 shares $25.27 million -0.6%N/A0.8 $32.50 2/26/2021782,400 shares $25.99 million +22.0%N/A0.9 $33.22 2/12/2021641,100 shares $25.93 million +25.0%3.8%0.7 $40.45 1/29/2021513,100 shares $8.02 million +28.2%4.5%0.8 $15.64 1/15/2021400,200 shares $6.88 million +4.7%3.5%3.3 $17.18 12/31/2020382,400 shares $7.22 million +27.3%3.4%3.2 $18.89 12/15/2020300,300 shares $5.69 million -11.6%2.7%3 $18.95 11/30/2020339,700 shares $6.61 million +3.9%3.0%3.8 $19.47 11/15/2020326,900 shares $6.15 million +47.0%2.8%3.8 $18.80 10/30/2020222,400 shares $3.83 million -12.3%1.9%2.9 $17.22 10/15/2020253,600 shares $3.79 million +2.3%2.2%3.7 $14.95 KALV Short Interest - Frequently Asked Questions What is KalVista Pharmaceuticals' current short interest? Short interest is the volume of KalVista Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of September 15th, investors have sold 11,160,000 shares of KALV short. Learn More on KalVista Pharmaceuticals' current short interest. What is a good short interest ratio for KalVista Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KALV shares currently have a short interest ratio of 9.0. Learn More on KalVista Pharmaceuticals's short interest ratio. Which institutional investors are shorting KalVista Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of KalVista Pharmaceuticals: Walleye Capital LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is KalVista Pharmaceuticals' short interest increasing or decreasing? KalVista Pharmaceuticals saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 11,160,000 shares, an increase of 5.7% from the previous total of 10,560,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does KalVista Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to KalVista Pharmaceuticals: Kiniksa Pharmaceuticals International, plc (3.28%), Mineralys Therapeutics, Inc. (14.99%), ImmunityBio, Inc. (8.95%), Immunovant, Inc. (22.88%), Bausch Health Cos Inc. (2.42%), Beam Therapeutics Inc. (25.21%), Catalyst Pharmaceuticals, Inc. (7.07%), Alvotech (1.35%), Tarsus Pharmaceuticals, Inc. (18.08%), IDEAYA Biosciences, Inc. (11.73%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Corporation ($8.81 billion), Canadian Natural Resources Limited ($5.82 billion), Reddit Inc. ($5.19 billion), Coinbase Global, Inc. ($4.52 billion), Robinhood Markets, Inc. ($4.30 billion), Charter Communications, Inc. ($3.75 billion), CoreWeave Inc. ($3.66 billion), Seagate Technology Holdings PLC ($3.57 billion), Live Nation Entertainment, Inc. ($3.33 billion), and Rocket Lab Corporation ($3.26 billion). View all of the most shorted stocks. What does it mean to sell short KalVista Pharmaceuticals stock? Short selling KALV is an investing strategy that aims to generate trading profit from KalVista Pharmaceuticals as its price is falling. KALV shares are trading up $0.10 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against KalVista Pharmaceuticals? A short squeeze for KalVista Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of KALV, which in turn drives the price of the stock up even further. How often is KalVista Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KALV, twice per month. The most recent reporting period available is September, 15 2025. More Short Interest Resources from MarketBeat Related Companies KNSA Short Squeeze MLYS Short Squeeze IBRX Short Squeeze IMVT Short Squeeze BHC Short Squeeze BEAM Short Squeeze CPRX Short Squeeze ALVO Short Squeeze TARS Short Squeeze IDYA Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:KALV) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
